Simulations Plus (NASDAQ:SLP) Releases FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 1.070-1.200 for the period, compared to the consensus EPS estimate of 0.900. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.7 million. Simulations Plus also updated its FY25 guidance to $1.07-$1.20 EPS.

Simulations Plus Stock Down 7.2 %

Shares of SLP stock opened at $28.21 on Thursday. The company’s 50 day moving average is $29.79 and its 200 day moving average is $34.00. The firm has a market cap of $566.60 million, a price-to-earnings ratio of 57.57 and a beta of 0.80. Simulations Plus has a 52-week low of $24.00 and a 52-week high of $51.22.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Wednesday, October 23rd. The technology company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. Simulations Plus had a net margin of 14.15% and a return on equity of 6.16%. The firm had revenue of $18.70 million for the quarter, compared to the consensus estimate of $19.73 million. During the same quarter in the previous year, the firm earned $0.18 EPS. The company’s quarterly revenue was up 19.9% compared to the same quarter last year. Analysts anticipate that Simulations Plus will post 1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research report on Wednesday. KeyCorp decreased their price objective on shares of Simulations Plus from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Wednesday. BTIG Research lowered their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Stephens started coverage on shares of Simulations Plus in a research report on Friday, November 15th. They set an “overweight” rating and a $39.00 price target on the stock. Finally, StockNews.com cut shares of Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.00.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $27.66, for a total value of $553,200.00. Following the transaction, the director now owns 3,462,584 shares in the company, valued at approximately $95,775,073.44. This represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 19.40% of the stock is owned by insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.